Dexamethasone augmentation in treatment-resistant depression

被引:66
|
作者
Dinan, TG
Lavelle, E
Cooney, J
Burnett, F
Scott, L
Dash, A
Thakore, J
Berti, C
机构
[1] Department of Psychological Medicine, St. Bartholomew's Hospital, London
[2] Department of Psychological Medicine, St. Bartholomew's Hospital
关键词
depression; treatment resistance; dexamethasone; fluoxetine; sertraline;
D O I
10.1111/j.1600-0447.1997.tb00374.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
A total of 10 patients who fulfilled DSM-III-R criteria for major depression were recruited to the study, each of whom had failed to respond to a 6-week course of treatment with either sertraline or fluoxetine. Each subject had baseline serum cortisol measurements together with a Hamilton depression (HAMD) score. All patients were started on dexamethasone (3 mg daily) for 4 days, while remaining on their antidepressant treatment. Further Hamilton ratings were made on days 5 and 21. Six patients showed a significant improvement, whilst two showed a minimal response. A good clinical response was associated with a high baseline cortisol level.
引用
收藏
页码:58 / 61
页数:4
相关论文
共 50 条
  • [1] Augmentation in treatment-resistant depression
    McIntyre, J.
    Moral, Ma Angels
    [J]. DRUGS OF THE FUTURE, 2006, 31 (12) : 1069 - 1081
  • [2] Augmentation strategies for treatment-resistant depression
    Carvalho, Andre F.
    Machado, Juliana Raulino
    Cavalcante, Joao L.
    [J]. CURRENT OPINION IN PSYCHIATRY, 2009, 22 (01) : 7 - 12
  • [3] Riluzole augmentation for treatment-resistant depression
    Sanacora, G
    Kendell, SF
    Fenton, L
    Coric, V
    Krystal, JH
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (11): : 2132 - 2132
  • [4] Quetiapine augmentation in treatment-resistant depression
    Sagud, M
    Mihaljevic-Peles, A
    Mueck-Seler, D
    Pivac, N
    Jakovljevic, M
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S444 - S444
  • [5] Antiepileptic drug augmentation for treatment-resistant depression
    Feiner, NF
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (08) : 361 - 362
  • [6] Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression
    Cantu, Filippo
    Ciappolino, Valentina
    Enrico, Paolo
    Moltrasio, Chiara
    Delvecchio, Giuseppe
    Brambilla, Paolo
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 280 : 45 - 53
  • [7] Lamotrigine as an augmentation agent in treatment-resistant depression
    Barbee, JG
    Jamhour, NJ
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (08) : 737 - 741
  • [8] Lithium or lamotrigine augmentation in treatment-resistant depression
    Rybakowski, J.
    Tuszewska, M.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S232 - S232
  • [9] Augmentation and combination strategies in treatment-resistant depression
    Fava, M
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 : 4 - 11
  • [10] Amantadine as augmentation therapy in the management of treatment-resistant depression
    Stryjer, R
    Strous, RD
    Shaked, G
    Bar, F
    Feldman, B
    Kotler, M
    Polak, L
    Rosenzcwaig, S
    Weizman, A
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (02) : 93 - 96